The Small Interfering RNA (siRNA) Therapeutics Market Size is valued at USD 1.6 Bn in 2023 and is predicted to reach USD 4.89 Bn by the year 2031 at a 15.0% CAGR during the forecast period for 2024-2031.
Small interfering RNA (siRNA) therapeutics describe a group of medicinal interventions that target disease-causing genes using small, engineered RNA molecules. Market expansion for siRNA treatments is driven by rising demand for precision medicine, new delivery platforms, and our increasing molecular understanding of disease causes. In addition, the increasing occurrence of chronic diseases presents numerous opportunities for creating and commercializing treatments based on small interfering RNAs.
Furthermore, market expansions are being propelled by the development of novel therapies, which in turn are being supported by rising investments in research initiatives from governments, private organizations, and pharmaceutical companies. In addition, the market of siRNA therapies is rising due to rising patient consciousness and the need for more precise, individualized treatments.
However, the market growth is hampered by the strict regulatory criteria of small interfering RNA (siRNA) therapeutics, therapies that can be expensive, and lengthy approval procedures for novel therapies, which are compounded by technical problems and obstacles to market expansion. In addition, because of the growing consensus among regulatory bodies regarding the therapeutic value of cancer, promising medications are being expedited through the review and approval processes, driving market growth. Furthermore, factors driving market expansion include an uptick in cancer HIV cases globally and a surge in research and development efforts related to creating these medications. Small interfering RNA therapeutics are in high demand because tumours, hereditary diseases, and viruses are on the rise worldwide.
The small interfering RNA (siRNA) therapeutics market is segmented based on product type, delivery methods, indication, route of administration (RoA) and End-User. The Delivery segment includes Lipid Nanoparticles (LNPs), Conjugates. According to the Indication segment, the market includes Hereditary Transthyretin-mediated Amyloidosis, Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1, Primary Hypercholesterolemia, Others. By RoA, the segmentation comprises Intravenous (IV) and Subcutaneous.
The lipid nanoparticle (LNPs) in small interfering RNA (siRNA) therapeutics market is expected to hold a major global market share owing to its capacity to improve the stability and transport of siRNA molecules.
The North American small interfering RNA (siRNA) therapeutics market is expected to report the biggest market share in revenue in the near future. It can be attributed to the heavy financial backing for pharmaceutical and biotech research, a well-developed healthcare system, and the headquarters of prominent pharmaceutical corporations. There is a high incidence of chronic diseases, helpful legislative frameworks, and substantial public financing for small interfering RNA treatment methods, which is growing the region's growth. In addition, Asia Pacific is estimated to grow very fast in the global small interfering RNA (siRNA) therapeutics market because of the big population and increasing requirement of high-quality healthcare in the region, and the increasing awareness of advanced treatment alternatives is driving the fast growth of the siRNA therapeutics industry in the Asia Pacific region.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 1.6 Bn |
|
Revenue Forecast In 2031 |
USD 4.89 Bn |
|
Growth Rate CAGR |
CAGR of 15.0% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product type, Delivery methods, Indication, route of administration (RoA) and end-user |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Alnylam, Silence Therapeutics, Silenseed Ltd, Sylentis, S.A., Sanofi Genzyme, Quark Pharmaceuticals, Dicerna Pharmaceuticals, Arrowhead Pharmaceuticals, Novartis, Novo Nordisk, Johnson & Johnson company, GSK, Aro Biotherapeutics and Other Market Players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Small Interfering RNA (siRNA) Therapeutics Market Snapshot
Chapter 4. Global Small Interfering RNA (siRNA) Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global Small Interfering RNA (siRNA) Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
Chapter 5. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 1: By Product Type, Estimates & Trend Analysis
5.1. Market Share by Product Type, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product Type:
5.2.1. Onpattro (Patisiran)
5.2.2. Givlaari (Givosiran)
5.2.3. Oxlumo (Lumasiran)
5.2.4. Leqvio (Inclisiran)
5.2.5. Amvuttra (Vutrisiran)
5.2.6. Rivfloza (Nedosiran)
5.2.7. Wainua (Eplontersen)
5.2.8. Others
Chapter 6. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 2: By Delivery Method, Estimates & Trend Analysis
6.1. Market Share by Delivery Method, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Delivery Method:
6.2.1. Lipid Nanoparticles (LNPs)
6.2.2. GalNAc-Conjugates
6.2.3. Other Delivery Systems
Chapter 7. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 3: By Indication,
Estimates & Trend Analysis
7.1. Market Share by Indication, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
7.2.1. Hereditary Transthyretin-mediated Amyloidosis
7.2.2. Acute Hepatic Porphyria
7.2.3. Primary Hyperoxaluria Delivery 1
7.2.4. Primary Hypercholesterolemia
7.2.5. Others
Chapter 8. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 4: By RoA, Estimates & Trend Analysis
8.1. Market Share by RoA, 2024 & 2034
8.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following RoA:
8.2.1. Intravenous (IV)
8.2.2. Subcutaneous
Chapter 9. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 5: By End-user, Estimates & Trend Analysis
9.1. Market Share by End-user, 2024 & 2034
9.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-user:
9.2.1. Hospitals and Clinics
9.2.2. Research Institutions
9.2.3. Pharmaceutical and Biotechnology Companies
9.2.4. Academic Institutions
Chapter 10. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Small Interfering RNA (siRNA) Therapeutics Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Product Type, 2021-2034
10.2.3. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Method, 2021-2034
10.2.4. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Indication, 2021-2034
10.2.5. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by RoA, 2021-2034
10.2.6. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by End-user, 2021-2034
10.3. Europe
10.3.1. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Product Type, 2021-2034
10.3.3. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Method, 2021-2034
10.3.4. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Indication, 2021-2034
10.3.5. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by RoA, 2021-2034
10.3.6. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by End-user, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Product Type, 2021-2034
10.4.3. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Method, 2021-2034
10.4.4. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Indication, 2021-2034
10.4.5. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by RoA, 2021-2034
10.4.6. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by End-user, 2021-2034
10.5. Latin America
10.5.1. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Product Type, 2021-2034
10.5.3. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Method, 2021-2034
10.5.4. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Indication, 2021-2034
10.5.5. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by RoA, 2021-2034
10.5.6. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by End-user, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Product Type, 2021-2034
10.6.3. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Method, 2021-2034
10.6.4. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Indication, 2021-2034
10.6.5. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by RoA, 2021-2034
10.6.6. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by End-user, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Companies with Approved Products:
11.2.1.1. Alnylam Pharmaceuticals
11.2.1.2. Novartis
11.2.1.3. Dicerna Pharmaceuticals (Novo Nordisk)
11.2.1.4. Ionis Pharmaceuticals
11.2.1.5. AstraZeneca
11.2.2. In Clinical Trials:
11.2.2.1. Arrowhead Pharmaceuticals
11.2.2.2. Silence Therapeutics
11.2.2.3. Wave Life Sciences
11.2.2.4. Sirnaomics
11.2.2.5. Sylentis S.A.
11.2.2.6. Quark Pharmaceuticals
11.2.2.7. Arbutus Biopharma
11.2.2.8. Phio Pharmaceuticals
11.2.2.9. Benitec Biopharma
11.2.2.10. Bio-Path Holdings
11.2.3. Companies With Delivery Platforms:
11.2.3.1. ABL Bio
11.2.3.2. Arbutus Biopharma
11.2.3.3. Calando Pharmaceuticals
11.2.3.4. Genecon Biotechnologies
Small Interfering RNA (siRNA) Therapeutics Market By Product Type-
Small Interfering RNA (siRNA) Therapeutics Market By Delivery Methods-
Small Interfering RNA (siRNA) Therapeutics Market By Indication-
Small Interfering RNA (siRNA) Therapeutics Market By RoA-
Small Interfering RNA (siRNA) Therapeutics Market By End-User-
Small Interfering RNA (siRNA) Therapeutics Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
